Indications |
Oral Monotherapy or adjunctive therapy in the treatment of partial seizures with or without secondary generalised tonic-clonic seizures Adult: Initially, 600 mg daily in 2 divided doses; increase at a max increments of 600 mg daily at wkly intervals depending on response. Maintenance: 600-1,200 mg daily. Adjunctive therapy/refractory patients switched from other anticonvulsants: Up to 2,400 mg daily. Child: >6 yr: 8-10 mg/kg daily in 2 divided doses; increase as necessary to max increments of 10 mg/kg daily at about wkly intervals to a max of 46 mg/kg daily. Maintenance in adjunctive therapy: 30 mg/kg daily.
Special Populations: Renal impairment: CrCl <30 mL/min: ½ of the usual starting dose increased at wkly intervals or longer. |
||||
Contraindications |
Hypersensitivity. Lactation. | ||||
Warnings / Precautions |
Cross-sensitivity to carbamazepine may occur. Do not discontinue abruptly. Renal and hepatic impairment. Patients at risk of hyponatraemia. May impair ability to drive or operate machinery. Pregnancy. | ||||
Adverse Reactions |
Dizziness, somnolence, headache, ataxia, fatigue, vertigo, nervousness, amnesia, abnormal thinking, insomnia, speech disorder, agitation, confusion; vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, constipation, gastritis, wt gain; abnormal gait, tremor, weakness, back pain, abnormal coordination, dysmetria, sprains/strains, muscle weakness; diplopia, nystagmus, abnormal vision and accommodation; hypotension, leg oedema; rash, acne; hyponatraemia; rhinitis, chest infection, epistaxis, sinusitis. Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis. Anaphylaxis and angioedema. |
||||
Overdose Reactions |
Symptoms: CNS depression (somnolence, ataxia). Treatment: Symptomatic and supportive. | ||||
Drug Interactions |
Reduced serum levels with carbamazepine, phenobarbitone, phenytoin, valproic acid. May reduce levels/effects of CYP3A4 substrates (e.g. benzodiazepines, calcium channel blockers, clarithromycin, ciclosporin, erythromycin, oestrogens, mirtazapine, nateglinide, nefazodone, nevirapine, protease inhibitors, tacrolimus, venlafaxine). May reduce efficacy of oral contraceptives. May reduce levels/effects of maraviroc. May increase levels of phenobarbitone, phenytoin. See Below for More oxcarbazepine Drug Interactions |
||||
Food Interactions |
Levels may be reduced with St John's wort. Evening primrose may reduce seizure threshold and reduce the effects of oxcarbazepine. | ||||
Mechanism of Actions |
Oxcarbazepine blocks voltage-sensitive sodium channels, which inhibits repetitive firing, stabilises hyperexcited neuronal membranes and decreases release of synaptic impulses. These effects may prevent the spread of epileptic seizures. Absorption: Well absorbed from the GI tract. Distribution: Monohydroxy metabolite: Widely distributed; protein-binding: About 40%, mainly to albumin. Oxcarbazepine and metabolite: Cross the placental barrier and enter breast milk. Metabolism: Metabolised in the liver to 10,11-dihydro-10-hydroxy-carbamazepine (principal metabolite; possesses antiepileptic activity). Excretion: Via urine (mainly as metabolites). Half-life: 2 hr (oxcarbazepine); 9 hr (monohydroxy metabolite). |
||||
Administration |
May be taken with or without food. |
||||
Storage Conditions |
Oral: Store at 25°C (77°F). | ||||
ATC Classification |
N03AF02 - oxcarbazepine ; Belongs to the class of carboxamide derivatives antiepileptic. | ||||
Storage |
Oral: Store at 25°C (77°F). | ||||
Available As |
|
Oxcarbazepine
Post Review about Oxcarbazepine Click here to cancel reply.
Oxcarbazepine Containing Brands
Oxcarbazepine is used in following diseases
Drug - Drug Interactions of Oxcarbazepine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.